SOHO 2018 | Brentuximab vedotin for treating Hodgkin Lymphoma
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses encouraging data on patients with Hodgkin lymphoma who received brentuximab vedotin who have shown complete response rates for more than five years now. These patients have not yet relapsed and are still off treatment, and Prof. Ansell suggests that these patients could potentially be cured. Prof. Ansell also stresses the need for more research into how long patients need brentuximab vedotin treatment for, as well as additional biological prognostic factors that can be targets for therapy. Despite genetic prognostic factors such as amplification of the 9p24.1 locus already offering a target for treatments from pembrolizumab and nivolumab, data suggests that this prognostic factor is not specific for patients who have relapsed.
